Q-omics provides the consensus-scored KIFBP profile across patient tissues and cancer cell-line models. KIFBP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KIFBP is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, KIFBP RNA expression shows 20,442 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where KIFBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIFBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIFBP survival associations across molecular data types. KIFBP RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIFBP RNA expression–survival associations across cancer types. High KIFBP expression shows unfavorable associations in HNSC, BLCA and ACC, but favorable associations in KIRC, LGG and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KIFBP RNA expression.
This table summarizes KIFBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIFBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIFBP shows lower tumor expression in KICH and higher tumor expression in LIHC, HNSC, BRCA, STAD and LUAD. The LIHC box plot shows higher KIFBP RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with KIFBP in patient tissues and cancer cell lines. In patient samples, KIFBP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIFBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
